Attached files
| file | filename |
|---|---|
| EX-99.1 - PROSPECTUS SUPPLEMENT - PHARMACEUTICAL HOLDRS TRUST | ss102005_ex9901-pharm.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
______________
Date of Report (Date of earliest event reported): October 4, 2010
MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED
Initial Depositor
(Exact name of Registrant as specified in its charter)
Pharmaceutical HOLDRS (SM) Trust
[Issuer with respect to the receipts]
|
DELAWARE
(State or other jurisdiction of
incorporation)
|
001-15653
Commission File Number
|
13-5674085
(I.R.S. Employer
Identification No.)
|
______________
One Bryant Park
New York, New York 10036
(Address of principal executive offices and zip code)
(212) 449-1000
(Registrant’s telephone number, including area code)
______________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01
|
Other Events
|
On September 28, 2010, the merger of Valeant Pharmaceuticals International and Biovail Corporation became effective. Also, effective September 28, 2010, Biovail Corporation changed its name to (New) Valeant Pharmaceuticals International, Inc. As a result, (Old) Valeant Pharmaceuticals International, Inc. will no longer be an underlying constituent of the Pharmaceutical HOLDRS Trust. In connection with the merger, (Old) Valeant Pharmaceuticals International, Inc. shareholders will receive 1.7809 shares of (New) Valeant Pharmaceuticals International, Inc. The Bank of New York Mellon will receive 1.7809 shares of (New) Valeant Pharmaceuticals International, Inc. per 100 share round lot of Pharmaceutical HOLDRS. As a result, once the allocation has been completed by The Depository Trust Company, creations of Pharmaceutical HOLDRS will require a deposit of 5.7809 shares of (New) Valeant Pharmaceuticals International, Inc. per 100 share round lot of Pharmaceutical HOLDRS.
|
Item 9.01.
|
Financial Statements and Exhibits
|
|
|
(d)
|
Exhibits
|
|
|
99.1
|
Pharmaceutical HOLDRS Trust Prospectus Supplement dated October 4, 2010 to Prospectus dated April 15, 2010.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED |
||||
| Date: October 4, 2010 | By: | /s/ Liam B. O’Neil | ||
| Name: | Liam B. O’Neil | |||
| Title: | Managing Director | |||
EXHIBIT INDEX
Number and Description of Exhibit
|
(99.1)
|
Pharmaceutical HOLDRS Trust Prospectus Supplement dated October 4, 2010 to Prospectus dated April 15, 2010.
|